CJASN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Published ahead of print on October 17, 2007
Clin J Am Soc Nephrol 2: 1140-1146, 2007
© 2007 American Society of Nephrology
doi: 10.2215/CJN.00830207

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
CJN.00830207v1
2/6/1140    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Warady, B. A.
Right arrow Articles by Dahl, N. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Warady, B. A.
Right arrow Articles by Dahl, N. V.

Clinical Pharmacology

Single-Dosage Pharmacokinetics of Sodium Ferric Gluconate Complex in Iron-Deficient Pediatric Hemodialysis Patients

Bradley A. Warady*, Paul A. Seligman{dagger}, and Naomi V. Dahl{ddagger}

* Department of Pediatrics, Section of Pediatric Nephrology, Children's Mercy Hospital, Kansas City, Missouri; {dagger} Department of Medicine, Division of Hematology, University of Colorado School of Medicine, Denver, Colorado; and {ddagger} Watson Laboratories, Morristown, New Jersey

Correspondence: Dr. Bradley A. Warady, Children's Mercy Hospital, 2401 Gillham Road, Kansas City, MO 64108. Phone: 816-234-3010; Fax: 816-234-3494; E-mail: bwarady{at}cmh.edu

Background and objectives: The clinical use of sodium ferric gluconate complex in iron-deficient pediatric patients receiving hemodialysis was recently approved. This study was designed to describe the pharmacokinetic parameters of the medication.

Design, setting, participants, & measurements: Iron-deficient pediatric (≤15 yr) hemodialysis patients were randomly assigned to two doses (1.5 and 3.0 mg/kg) of sodium ferric gluconate complex. Blood samples taken during a 1-h infusion and at multiple intervals during 48 h were analyzed for total iron, transferrin-bound iron, and sodium ferric gluconate complex–bound iron.

Results: Forty-nine patients (mean age 12.3 ± 2.5 yr) participated in the study. Mean serum iron concentrations rapidly increased in a dosage-dependent manner. A rapid rise in total serum iron was followed by a slower, less prominent rise in transferrin-bound iron. This was qualitatively confirmed by visualization of the transferrin bands from polyacrylamide gel electrophoresis. Single-dose pharmacokinetics of sodium ferric gluconate complex–bound iron was described using noncompartmental analytical methods. Mean values for the 1.5 mg/Kg dose were as follows: t1/2 2.0 ± 0.7 h, Cmax 1287 mcg/dl, Tmax 1.1 ± 0.23 h, Cl 0.69 ± 0.50 L/h, Vd 1.6 ± 0.6 L, AUC0-{infty}. 9499 ± 4089 mcg · hr/dl.

Conclusions: The infusion of sodium ferric gluconate complex to pediatric patients who receive hemodialysis appears to result in a delayed transfer of iron to transferrin, likely after an initial movement through the reticuloendothelial system. Differences noted between the pediatric and adult pharmacokinetic data may result from the unique aspects of the study populations and the respective study designs.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Society of Nephrology.